ASCO updates recs on potentially curable pancreatic cancer

ASCO updates recs on potentially curable pancreatic cancer
(HealthDay)—Guidelines relating to the appropriate adjuvant regimen for patients with pancreatic cancer have been updated in light of new evidence, according to a special article published online April 11 in the Journal of Clinical Oncology.

Alok A. Khorana, M.D., from the Cleveland Clinic, and colleagues reviewed recent evidence from the ESPAC-4 multicenter, international phase III trial to revise guideline recommendations regarding the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone an R0 or R1 resection of their primary tumor. The study compared and capecitabine with gemcitabine monotherapy in 730 evaluable patients.

The researchers found that median overall survival was improved to 28.0 months in the doublet arm, compared with 25.5 months in the gemcitabine-alone arm (hazard ratio, 0.82). Both arms had similar grade 3 and 4 adverse events. Based on these findings, the authors recommend that patients with resected who did not receive preoperative therapy should be offered six months of . In the absence of concerns for toxicity or tolerance, the doublet regimen of gemcitabine and capecitabine is preferred; monotherapy with gemcitabine or fluorouracil plus folinic acid can be offered as an alternative. Assuming complete recovery, adjuvant treatment should be initiated within eight weeks of .

"The doublet regimen of gemcitabine and has shown improvement in survival, as demonstrated in a randomized trial with appropriate data and safety monitoring, and is therefore preferred," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.


Explore further

Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer

More information: Abstract
Full Text
Journal information: Journal of Clinical Oncology

Copyright © 2017 HealthDay. All rights reserved.

Citation: ASCO updates recs on potentially curable pancreatic cancer (2017, April 17) retrieved 16 June 2019 from https://medicalxpress.com/news/2017-04-asco-recs-potentially-curable-pancreatic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more